Merck buys controlling stake in Physicians Interactive

Share this article:

Merck's Global Health Innovation Fund (GHIF) has taken a controlling interest in digital physician marketing firm Physicians Interactive, MM&M has learned. Financial terms of the deal were not disclosed.

The takeover of Marlborough, MA-based Physician's Interactive, which provides online and mobile clinical tools and marketing to doctors like e-sampling and interactive education programs, follows a $17-million stake taken by GHIF in January 2012.

By expanding its stake in PI, Merck is deepening its relationship with a well-established provider of non-personal promotion to HCPs, a commodity in this era when drug makers are fielding much slimmer sales forces.

“PI offers low-cost, multi-channel, integrated marketing solutions and applications, generated from its online platform of user-generated, proprietary and public data, to enable medical professionals to deliver better patient care,” said Merck in a statement. “These programs can be used to supplement currently promoted products as well as non-promoted and orphaned products that still have value to physicians and patients.”

“PI will operate independently and maintain its own governance, policies and corporate IT infrastructure to ensure the security of its customers' data and intellectual property,” Merck added.

The previous majority owner of PI was private equity firm Perseus Capital.

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...